top of page

<<  < 1 2 3 4 5 6 7 8 9 > >> 

723. Huang, H., H. Tanaka, B.D. Hammock and C. Morisseau. 2009. Novel and highly sensitive fluorescent assay for leucine aminopeptidases. Analytical Biochemistry 391:11-16. [Download]

724.  Simpkins, A.N., R.D. Rudic, D.A. Schreihofer, S. Roy, M. Manhiani, H-J. Tsai, B.D. Hammock and J.D. Imig. 2009. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Amer. J. Pathol. 174(6):2086-2095. [Download]

726. Luria, A., C. Morisseau, H-J. Tsai, J. Yang, B. Inceoglu, B. Taeye, S.M. Watkins, M.M. Wiest, J.B. German and B.D. Hammock. 2009. Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. Am J Physiol Endocrinol Metab. 297:E375-E383. PMCID: PMC2724109. [Download]

727. Liu, J-Y., S-H. Park, C. Morisseau, S. Hwang, B.D. Hammock and R.H. Weiss. 2009. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther. 8(6):2193-2203. [Download]

730.  Falck, J.R., R. Kodela, R. Manne, K. Atcha, N. Puli, N. Dubasi, V.L. Manthati, J.H. Capdevila, X-Y. Yi, D.H. Goldman, C. Morisseau, B.D. Hammock and W.B. Campbell. 2009. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) Surrogates Containing Epoxide Bioisosteres: Influence upon Vascular Relaxation and Soluable Epoxide Hydrolase Inhibition. J. Med. Chem. 52:5069-5075. PMID:19653681. PMCID: PMC2888647. [Download]

731. Shen, S., F. Zhang, S. Zeng, Y. Tian, X. Chai, S. Gee, B.D. Hammock and J. Zheng.  2009.  Development of enantioselective polyclonal antibodies to detect styrene oxide protein adducts.  Anal. Chem. 81(7):2668-2677. [Download]

732.  Matveeva, E.G., C. Morisseau, M.H. Goodrow, C. Mullin and B.D. Hammock. 2009. Tryptophan Fluorescence Quenching by Enzyme Inhibitors As a Tool for Enzyme Active Site Structure Investigation: Epoxide Hydrolase. Current Pharmaceutical Biotechnology. 10(6):589-599. [Download]

733. Manhiani, M., J.E. Quigley, S.F. Knight, S. Tasoobshirazi, T. Moore, M.W. Brands, B.D. Hammock and J.D. Imig. 2009.  Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal Physiol. 297:F740-F748. PMCID: PMC2739707. [Download]

734. Yang, J., K. Schmelzer, K. Georgi and B.D. Hammock. 2009. Quantitative Profiling Method for Oxylipin Metabolome by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry. Anal. Chem. 81(19):8085-93. PMID:19715299. [Download]

735. Imig, J.D. and B.D. Hammock. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8(10):794-805. PMID: 19794443. PMCID: PMC3021468. [Download]

737. Barbosa-Sicard, E., T. Frömel, B. Keserü, R.P. Brandes, C. Morisseau, B.D. Hammock, T. Braun, M. Krüger and I. Fleming. 2009.  Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J. Biol. Chem. 284(41):28156-28163. PMCID: PMC2788866. [Download]

738. Lu, C., R. Schoenfeld, Y. Shan, H-J. Tsai, B. Hammock and G. Cortopassi. 2009. Frataxin deficiency induces Schwann cell inflammation and death. Biochimica et Biophysica. 1792:1052-1061. PMID:19679182. [Download]

739. Li, N., J-Y. Liu, V. Timofeyev, H. Qiu, S. Hwang, D. Tuteja, L. Lu, J. Yang, H. Mochida, R. Low, B.D. Hammock and N. Chiamvimonvat. 2009. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. J Mol Cell Cardiol. 47(6):835-845. PMID: 19716829. [Download]

740. Morisseau, C., O. Merzlikin, A. Lin, G. He, W. Feng, I. Padilla, M.S. Denison, I.N. Pessah and B.D. Hammock. 2009. Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors. Environ Health Perspect. 117(12):1867-1872. PMCID: PMC2799460. [Download]

741. Chawengsub, Y., K.M. Gauthier, K. Nithipatikom, B.D. Hammock, J.R. Falck, D. Narsimhaswamy and W.B. Cambell. 2009. Identification of 13-hydroxy-14, 15-epoxyeicosatrienoic acid as an acid-stable endothelium-derived hyperpolarizing factor in rabbit arteries. J. Biol. Chem. 284(45):31280-31290. PMCID: PMC2781526. [Download]

742. Keserü, B., E. Barbosa-Sicard, R.T. Schermuly, H. Tanaka, B.D. Hammock, N. Weissmann, B. Fisslthaler and I. Fleming. 2010. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res. 85(1):232-240. PMCID: PMC2860707. [Download]

743. Lyer, A., D.P. Fairlie, J.B. Prins, B.D. Hammock and L. Brown. 2010. Inflammatory lipid mediators in adipocyte function and obesity. Nat. Rev. Endocrinol. 6(2):71:82. [Download]

744. De Taeye, B.M., C. Morisseau, J. Coyle, J.W. Covington, A. Luria, J. Yang, S.B. Murphy, D.B. Friedman, B.D. Hammock and D.E. Vaughan. 2010. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring). 18(3):489-98. PMCID: PMC2864128. [Download]

745. Hall, L.M., M.G. Kimlin, P.A. Aronov, B.D. Hammock, J.R. Slusser, L.R. Woodhouse and C.B. Stephensen. 2010. Vitamin D intake needed to maintain target serum 25-hydroxyvitamin D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. J. Nutr. 140(3):542-550. PMCID: PMC2821886. [Download]

748. Chaudhary, K.R., M. Abukhashim, S.H. Hwang, B.D. Hammock and J.M. Seubert. 2010. Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J. Cardiovasc. Pharmacol. 55(1):67-73. PMCID: PMC2824072. [Download]

749.  Certíková Chábová, V., A. Walkowska, E. Kompanowska-Jezierska, J. Sadowski, P. Kujal, Z. Vernerová, Z. Vanourková, L. Kopkan, H.J. Kramer, J.R. Falck, J.D. Imig, B.D. Hammock, I Vanecková and L. Cervenka. 2010. Combined inhibition of 20-hydroxyeicosatetaenoic acid formation and of epoxyeicosatrienoic acids degration attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 118(10):617-632. PMCID: PMC2854172. [Download]

750. Liu, J-Y., J. Yang, B. Inceoglu, H. Qiu, A. Ulu, S-H. Hwang, N. Chiamvimonvat and B.D. Hammock. 2010. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol. 79(6):880-887. PMCID: PMC3285377. [Download]

751. Bahl, D.C., C. Morisseau, J.M. Bomberger, B.A. Stanton, B.D. Hammock, G.A. O'Toole and D.R. Madden. 2010. Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J Bacteriol. 192(7):1785-1795. PMCID: PMC2838060. [Download]

753. Alihosseini, F., J. Lango, K-S. Ju, B.D. Hammock and G. Sun. 2010. Mutation of bacterium Vibrio gazogenes for selective preparation of colorants. Biotechnol. Prog. 26(2):352-360. PMCID: PMC2864118. [Download]

754. Townsley, M.I., C. Morriseau, B. Hammock and J.A. King. 2010. Impact of epoxyeicosatrienoic acids in lung ischemia-reperfusion injury. Microcirculation 17(2):137-146. PMCID: PMC2923642. [Download]

757. Wang, Y.X., A. Ulu, L.N. Zhang and B.D. Hammock. 2010. Soluble epoxide hydrolase in atherosclerosis. Curr. Atheroscler. Rep. 12(3):174-183. PMID: 20425256. PMCID: PMC2857794. [Download]

758. Kubala, L., K.R. Schmelzer, A. Klinke, H. Kolarova, S. Baldus, B.D. Hammock and J.P. Eiserich. 2010. Modulation of arachidonic and linoleic acid metabolites in myeloperoxidase-deficient mice during acute inflammation. Free Radic. Biol. Med. 48(10):1311-1320. PMCID: PMC2856720. [Download]

760. Revermann, M., M. Schloss, E. Barbosa-Sicard, A. Mieth, S. Liebner, C. Morisseau, G. Geisslinger, R.T. Schermuly, I. Fleming, B.D. Hammock and R.P. Brandes. 2010. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. 30(5):909-914. PMCID: PMC2919323. [Download]

761. Simpkins, A.N., R.D. Rudic, S. Roy, H.J. Tsai, B.D. Hammock and J.D. Imig. 2009. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 298(3):H795-H806. PMCID: PMC2838550. [Download]

762. Tsai, H-J., S.H. Hwang, C. Morisseau, J. Yang, P.D. Jones, T. Kasagami, I-H. Kim and B.D. Hammock. 2010. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur. J. Pharm. Sci. 40(3):222-238. PMCID: PMC3285443. [Download]

763.  Nording, M.L., J. Yang, C.M. Hegedus, A. Bhushan, N.J. Kenyon, C.E. Davis and B.D. Hammock. 2010. Endogenous levels of five fatty acid metabolites in exhaled breath condensate to monitor asthma by high-performance liquid chromatography: electrospray tandem mass spectrometry. IEEE Sens J. 10(1):123-130. PMID: 21103452. PMCID: PMC2981865. [Download]

764.  Jung, O., F. Jansen, A. Mieth, E. Barbosa-Sicard, R.U. Pliquett, A. Babelova, C. Morisseau, S.H. Hwang, C. Tsai, B.D. Hammock, L. Schaefer, G. Geisslinger, K. Amann and R.P. Brandes. 2010. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One 5(8):e11979. PMCID: PMC2915917. [Download]

768. Luo, P., H-H. Chang, Y. Zhou, S. Zhang, S.H. Hwang, C. Morisseau, C-Y. Wang, E.W. Inscho, B.D. Hammock and M.H. Wang. 2010. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 334(2):430-438. PMID: 20439437. PMCID: PMC2913776. [Download]

769. Liu, J-Y., N. Li, J. Yang, N. Li, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu and B.D. Hammock. 2010. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A. 107(39):17017-17022. PMCID: PMC2947894. [Download]

770. Norwood, S., J. Liao, B.D. Hammock and G-Y. Yang. 2010. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am. J. Transl. Res. 2(4):447-457. PMCID: PMC2923867. [Download]

771. Rayo, J., L. Muñoz, G. Rosell, B.D. Hammock, A. Guerrero, F.J. Luque and R. Pouplana. 2010. Reactivity versus steric effects in flourniated ketones as esterase inhibitors: a quantum mechanical and molecular dynamics study. J. Mol. Model. 16(11):1753-1764. PMCID: PMC3014912. [Download]

772.  Rose, T.E., C. Morisseau, J-Y. Liu, B. Inceoglu, P.D. Jones, J.R. Sanborn and B.D. Hammock. 2010. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure – activity relationships, pharmacokinetics, and reduction of inflammatory pain. J. Med. Chem. 53(19):7067-7075. PMCID: PMC3285450. [Download]

773. Morisseau, C., B. Inceoglu, K. Schmelzer, H-J. Tsai, S.L. Jinks, C.M. Hegedus and B.D. Hammock. 2010. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res. 51(12):3481-3490. PMCID: PMC2975720. [Download]

776. Huang, S-X., H-Y. Li, J-Y. Liu, C. Morisseau, B.D. Hammock and Y-Q. Long. 2010. Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved Pharmacokinetic Properties. J Med Chem. 53(23):8376-8386. PMCID: PMC3070159. [Download]

777.  Zhang, D., D. Ai, H. Tanaka, B.D. Hammock and Y. Zhu. 2010. DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1 dependent mechanism. Biochim. Biophs. Acta 1799(9):659-667. [Download]

778.  Honetschlägerová, Z., Z Husková, Z. Vanourková, A. Sporková, H.J. Kramer, S.H. Hwang, H-J. Tsai, B.D. Hammock, J.D. Imig, L. Cervenka and L. Kopkan. 2011. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J. Physiol. 589(1):207-219. [Download]

780.  Anandan, S-K., H.K. Webb, D. Chen, Y-X. Wang, B.R. Aavula, S. Cases, Y. Cheng, Z.N. Do, U. Mehra, V. Tran, J. Vincelette, J. Waszczuk, K. White, K.R. Wong, L-N. Zhang, P.D. Jones, B.D. Hammock, D.V. Patel, R. Whitcomb, D.E. MacIntyre, J. Sabry and R. Gless. 2011. 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg. Med. Chem. Lett. 21(3):983-988. [Download]

781.  Charles, R.L., J.R. Burgoyne, M. Mayr, S.M. Weldon, N. Hubner, H. Dong, C. Morisseau, B.D. Hammock, A. Landar and P. Eaton. 2011. Redox regulation of soluble epoxide hydrolase by 15-Deoxy-?-Prostaglandin J2 controls coronary hypoxic vasodilation. Circ. Res. 108:324-334. PMCID:PMC 3259859. [Download]

782.  Schebb, N.H., B. Inceoglu, T. Rose, K. Wagner and B.D. Hammock. 2011. Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. Anal. Methods 3(2):420-428. PMCID: PMC3110015. [Download]

783.  Qiu, H., N. Li, J-Y. Liu, T.R. Harris, B.D. Hammock and N. Chiamvimonvat. 2011. Soluble epoxide hydrolase inhibitors and heart failure. Cardiovasc. Ther. 29(2):99-111. PMCID: PMC3325372. [Download]

784.  Li, N., J-Y. Liu, H. Qiu, T.R. Harris, P. Sirish, B.D. Hammock and N. Chiamvimonvat. 2011. Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease. Congest. Heart Fail. 17(1):42-46. PMCID: PMC3583533. [Download]

786.  Aboutabl, M.E., B.N. Zordoky, B.D. Hammock and A.O. El-Kadi. 2011. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J. Cardiovasc. Pharmacol. 57(3):273-281. [Download]

787.  Kim, I.H., Y.K. Park, B.D. Hammock and K. Nishi. 2011. Structure – activity relationships of cycloalkylamide derivatives as inhibitors of the soluble epoxide hydrolase. J. Med. Chem. 54(6):1752-1761. [Download]

788.  Inceoglu, B., K. Wagner, N.H. Schebb, C. Morisseau, S.L. Jinks, A. Ulu, C. Hegedus, T. Rose, R. Brosnan and B.D. Hammock. 2011. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A. 108(12):5093-5097. PMCID: PMC3064364. [Download]

789.  Koeners, M.P., S. Wesseling, A. Ulu, R.L. Sepúlveda, C. Morisseau, B. Braam, B.D. Hammock and J.A. Joles. 2011. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive Rats. Am. J. Physiol. Endocrinol. Metab. 300(4):E691-698. PMCID: PMC3074945. [Download]

791.  Wagner, K., B. Inceoglu, S.S. Gill and B.D. Hammock. 2011. Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: Novel mediators of pain reduction. J. Agric. Food Chem. 59(7):2816-2824. [Download]

792.  Schebb, N.H., B. Inceoglu, K.C. Ahn, C. Morisseau, S.J. Gee and B.D. Hammock. 2011. Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ. Sci. Technol. 45(7):3109-3115. [Download]

793.  Abdu, E., D.A. Bruun, D. Yang, J. Yang, B. Inceoglu, B.D. Hammock, N.J. Alkayed and P.J. Lein. 2011. Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures. J. Neurochem. 117:632-642. [Download]

794.  Hwang, S.H., K.M. Wagner, C. Morisseau, J-Y. Liu, H. Dong, A.T. Wecksler and B.D. Hammock. 2011. Synthesis and structure – activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J. Med. Chem. 54(8):3037-3050. PMCID: PMC3281519. [Download]

795.  Schebb, N.H., M. Huby, C. Morisseau, S.H. Hwang and B.D. Hammock. 2011. Development of an online SPE-LC-MS-based assay using endogenous substrate for the investigation of soluble epoxide hydrolase (sEH) inhibitors. Anal. Bioanal. Chem. 400(5):1359-1366. PMCID:PMC 3081056. [Download]

796.  Barhoumi, R., Y. Mouneimne, E. Ramos, C. Morisseau, B.D. Hammock, S. Safe, A.R. Parrish and R.C. Burghardt. 2011. Multiphoton spectral analysis of benzo[a]pyrene uptake and metabolism in a rat liver cell line. Toxicol. Appl. Pharmacol. 253(1):45-56. PMCID: PMC3081912. [Download]

797.  Morisseau, C., M. Bernay, A. Escaich, J.R. Sanborn, J. Lango and B.D. Hammock. 2011. Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies. Anal. Biochem. 414:154-162. PMCID:PMC 3090455. [Download]

798.  Yang, J., H. Dong and B.D. Hammock. 2011. Profiling the regulatory lipids: Another systemic way to unveil the biological mystery. Curr. Opin. Lipidol. 22(3):197-203. [Download]

800.  Luria, A., A. Bettaieb, Y. Xi, G.J. Shieh, H.C. Liu, H. Inoue, H.J. Tsai, J.D. Imig, F.G. Haj and B.D. Hammock. 2011. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A. 108(22):9038-9043. PMCID:PMC3107315. [Download]

801. Jiang, H., J. Quilley, A.B. Doumad, A.G. Zhu, J.R. Falck, B.D. Hammock, C.T. Stier Jr., and M.A. Carroll. 2011. Increases in plasma trans-EETs are associated with blood pressure reduction in spontaneously hypertensive rats. Am. J. Physiol Heart Circ Physiol. 300(6):H1990-1996. PMCID: PMC3119086. [Download]

802. Sporkova, A., L. Kopkan, S. Varcabova, Z. Huskova, S.H. Hwang, B.D. Hammock, J.D. Imig, H.J. Kramer and L. Cervenka. 2011. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300(6):R1468-1475. PMCID: PMC3119161. [Download]

804. Zivkovic, A.M., N. Telis, J.B. German and B.D. Hammock. 2011. Dietary omega-3 fatty acids in the modulation of inflammation and metabolic health. California Agr. 65:106-111. [Download]

805. Schebb, N.H., I. Flores, T. Kurobe, B. Franze, A. Ranganathan, B.D. Hammock and S. Teh. 2011. Bioconcentration, metabolism and excretion of triclocarban in Qurt medaka (Oryzias latipes). Aquatic Toxicology. 105(3-4): 448– 454. PMCID: PMC3236035. [Download]

806. Liu, X., C. Li, S.H. Hwang, B.D. Hammock, J.R. Falck, R.J. Roman, D.R. Harder and R.C. Koehler. 2011. Epoxyeicosatrienoic acid-dependent cerebral vasodilation evoked by metabotropic glutamate receptor activation in vivo. American J Physiology: Heart and Circulatory Physiology. 301(2):H373-81. PMCID: PMC3154671. [Download]

807. Hasenau, A.L., G. Nielsen, C. Morisseau, B.D. Hammock, H. Wulff and R. Köhler. 2011. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate conductance Ca(2+)-activated K(+)-channels. Acta Physiol. (Oxf). 203(1):117–126. PMCID: PMC3139805. [Download]

808. Liu, J.Y., H. Qiu, C. Morisseau, S.H. Hwang, H.J. Tsai, A. Ulu, N. Chiamvimonvat and B.D. Hammock. 2011. Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicol. Appl. Pharmacol. 255:200-206. PMCID:PMC3156297. [Download]

809. Hammock, B.D., K. Wagner, and B. Inceoglu. 2011. The soluble epoxide hydrolase as a pharmaceutical target for pain management. Pain Manage. 1(5): 383-386. [Download]

810. Yin, Z., V. Pintea, Y. Lin, B.D. Hammock and M.A. Watsky. 2011. Vitamin D enhances corneal epithelial barrier function. Invest. Ophthalmol.Vis. Sci. 52(10):7359-7364. PMCID: PMC3183972. [Download]

812. Honetschlägerová, Z, A. Sporková, L. Kopkan, Z. Husková, S.H. Hwang, B.D. Hammock, J.D. Imig, H.J. Kramer and L. ?ervenka. 2011. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of angiotensin II-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 29(8):1590-1601. PMCID: PMC3777565. [Download]

813. Davis, B.B., J.Y. Liu, D.J. Tancredi, L. Wang, S.I. Simon, B.D. Hammock and K.E. Pinkerton. 2011. The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment. Biochem. Biophys. Res. Commun. 410(3):494-500. PMCID: PMC3166856. [Download]

816. Wagner, K., B. Inceoglu and B.D. Hammock. 2011. Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. Prostaglandins and Other Lipid Mediat. 96(1-4)76-83. PMCID: PMC3215909. [Download]

817. Ionue, H., S.H. Hwang, A.T. Wecksler, B.D. Hammock and R.H. Weiss. 2011. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther. 12(9):827-36. [Download]

818. Yang, Jun, H. Dong, B.D. Hammock. 2011. EETs and oxo-ETE in airway diseases. In: Obstructive Airway Disease. Role of Lipid Mediators. pp.125-150. CRC Press. [Download]

823. Ulu, A., S.E. Appt, C. Morisseau, S.H. Hwang, P.D. Jones, T.E. Rose, H. Dong, J. Lango, J. Yang, H.J. Tsai, C. Miyabe, C. Fortenbach, M.R. Adams and B.D. Hammock. 2012. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol. 165(5):1401-12. [Download]

824. Pecic, S., S.X. Deng, C. Morisseau, B.D. Hammock and D.W. Landry. 2012. Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 22(1):601-5. [Download]

825. Panigrahy, D.,M.L. Edin, C.R. Lee, S. Huang, D.R. Bielenberg, C.E. Butterfield, C.M. Barnés, A. Mammoto, T. Mammoto, A. Luria, O. Benny, D.M. Chaponis, A.C. Dudley, E.R. Greene, J.A. Vergilio, G. Pietramaggiori, S.S. Scherer-Pietramaggiori, S.M. Short, M. Seth, F.B. Lih, K.B. Tomer, J. Yang, R.A. Schwendener, B.D. Hammock, J.R. Falck, V.L. Manthati, D.E. Ingber, A. Kaipainen, P.A. D’Amore, M.W. Kieran and D.C. Zeldin. 2012. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest. 122(1):178-91.  PMCID: PMC3248288. [Download]

826. Hou, H.H., B.D. Hammock, K.H. Su, C. Morisseau, Y.R. Kou, S. Imaoka, A. Oguro, S.K. Shyue, J.F. Zhao and T.S. Lee. 2012. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc Res. 93(1):120-9. PMCID: PMC3243038. [Download]

828. Landeros, R.V., C. Morisseau, H.J. Yoo, S.H. Fu, B.D. Hammock and B.C. Trainor. 2012. Corncob bedding alters the effects of estrogens on aggressive behavior and reduces estrogen receptor alpha expression in the brain. Endocrinology. 153(2):949-53. PMCID: PMC 3275391. [Download]

830. Lundström, S.L. , B. Levänen, M.L. Nording, A. Klepczynska-Nyström, M. Sköld, J.Z Haeggström, J. Grunewald, M. Svartengren, B.D. Hammock, B-M. Larsson, A. Eklund, C.E Wheelock and Å.M. Wheelock. 2011. Asthmatics exhibit altered oxylipin profiles compared to healthy individuals after subway air exposure. PLoS One. 6(8):e23864. PMCID: PMC 3163588. [Download]

831. Neckár, J., L. Kopkan, Z. Husková, F. Kolár, F. Papoušek,  H.J. Kramer, S.H. Hwang, B.D. Hammock, J.D. Imig, J. Malý, I. Netuka, B. Oštádal and L. Cervenka. 2012. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-oxy]-benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin.Sci (Lond). 122(11):513-25. [Download]

832. Iyer, A., K. Kauter, M.A. Alam, S.H. Hwng, C. Morisseau, B.D. Hammock and L. Brown. 2012. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res. 2012:758614. PMCID: PMC3191770. [Download]

833. Shen, H., and B.D. Hammock. 2012. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem. 55(5):1789-808. [Download]

834. Helferich, W.G., M.H. Silva, W.T. Flueck, B.D. Hammock and L.R. Shull. 1987. Xenobiotic biotransformation in livers and lungs of adult black-tailed deer: comparison with domestic goat and sheep. Comp Biochem Physiol C. 88(1):145-49. [Download]

835. Lundström, S.L., J. Yang, H.J. Kallberg, S. Thunberg, G. Gafvelin, J.Z. Haeggstrom, R. Gronneberg, J. Grunewald, M. van Hage, B.D. Hammock, A. Eklund, A.M. Wheelock and C.E. Wheelock. 2012. Allergic asthmatics show divergent lipid mediator profiles from healthy controls both at baseline and following birch pollen provocation. PLoS One. 7(3):e33780. PLoS One. 7(3):e33780. PMCID:PMC3305349. [Download]

836. Duan, H.Y., K. Yoshimura, N. Kobayashi, K. Sugiyama, J. Sawada, Y. Saito, C. Morisseau, B.D. Hammock and T. Akatsuka. 2012. Development of monoclonal antibodies to himan microsomal epoxide hydrolase and analysis of preneoplastic antigen-like molecules. Toxicol Appl Pharmacol. 260(1):17-26. PMCID: PMD3319115. [Download]

837. Duan, H.Y., A. Takagi, H. Kayano, I. Koyama, C. Morisseau, B.D. Hammock and T. Akatsuka. 2012. Monoclonal antibodies reveal multiple forms of expression of human microsomal epoxide hydrolase. Toxicol Appl Pharmacol. 260(1):27-34. PMCID: PMC3319120. [Download]

838. Zhang D., X. Xie, Y. Chen, B.D. Hammock, W. Kong and Y. Zhu. 2012. Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vito and in vivo. Circ Res. 110(6):808-17. [Download]

839. Schebb, N.H., K.C. Ahn, H. Dong, S.J. Gee and B.D. Hammock. 2012. Whole blood is the sample matrix of choice for bio-monitoring of human triclocarban exposure. Chemosphere. 87(7):825-27. [Download]

840. Morisseau, C., N.H. Schebb,  H. Dong, A. Ulu, P.A. Aronov and B.D. Hammock. 2012. Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. Biochem Biophys Res Commun. 419(4):796-800. PMCID: PMC3313618. [Download]

842. Zolkowska, D., C.N. Banks, A. Dhir, B. Inceoglu, J.R. Sanborn, M.R. McCoy, D.A. Bruun, B.D. Hammock, P.J. Lein and M.A. Rogawski. 2012. Characterization of seizures induced by acute and repeated exposure to tetramethylenedisulfotetramine. J Pharmacol Exp Ther. 341(2):435-46. PMCID: PMC3336809. [Download]

843. Wang, L., J. Yang, L. Guo, D. Uyeminami, H. Dong, B.D. Hammock and K.E. Pinkerton. 2012. Use of a soluble epoxide hydrolase inhibitors in smoked-induced chronic obstructive pulmonary disease. Am J Respir Cell Mol Bio. 46(5):614-22. PMICD: PMC3359909. [Download]

845. Yang, J., J.P. Eiserich, C.E. Cross, B.M. Morrissey and B.D. Hammock. 2012. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic Biol Med. 53(1): 160-71. PMICD: PMC3359909. [Download]

846. Insawang, T., C. Selmi, U. Cha’on, S. Pethlert, P. Yongvanit, P. Areejitranusorn, P. Boonsiri, T. Khampitak, R. Tangrassameeprasert, C. Pinitsoontorn, V. Prasongwattana, E.M. Gershwin and B.D. Hammock. 2012. Monosodium glutamate (MSG) intake is associated with the prevalence of metabolic syndrome in a rural Thai population. Nutr Metab (Lond). 9(1):50. PMCID: PMC3583269. [Download]

847. Jiang, H., F.E. Harrison, K. Jain, S. Benjamin, J.M. May, J.P. Graves, D.C. Zeldin, J.R. Falck, B.D. Hammock and J.C. McGiff. 2012. Vitamin C activation of the biosynthesis of epoxyeicosatrienoic acids. Adv Biosci Biotechno. 3(3):204-18. [Download]

848. Frömel T., B. Jungblut, J. Hu, C. Trouvain, E. Barbosa-Sicard, R. Popp, S. Liebner, S. Dimmeler, B.D. Hammock and I. Fleming. 2012. The soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc Natl Acad Sci U S A. 109(25):9995-10000. PMCID: PMC3382493. [Download]

849. Schebb N.H., B.A. Buchholz, B.D. Hammock, and R.H. Rice. 2012. Metabolism of the antibacterial triclocarban by human epidermal keratinocytes to yield protein adducts. J Biochem Mol Toxicol.26(6):230-34. PMCID: PMC3522462. [Download]

850. Liu, Y., H.X. Dang, D. Li, W. Pang, B.D. Hammock and Y. Zhu. 2012. Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS One. 7(6):e39165. PMCID: PMC3375303. [Download]

851. Stephensen, C.B., M. Zerofsky, D.J. Burnett, Y.P. Lin, B.D. Hammock, L.M. Hall and T. McHugh. 2012. Ergocalciferol from mushrooms or supplements consumed with a standard meal increases 25-hydroxyergocalciferol but decreases 25-hydroxycholecalciferol in the serum of healthy adults. J Nutr. 142(7):1246-52. [Download]

852. Inceoglu, B., J. Yang, C. Hegedus, B. Hammock and S. Schaefer. 2012. Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice. J Cardiovasc Pharmacol. 60(1):70-75. PMCID: PMC3396292. [Download]

853. Eiserich, J. P., J. Yang, B.M. Morrissey, B.D. Hammock and C.E. Cross. 2012. Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions. Ann N Y Acad Sci. 1259(1):1-9. PMCID: PMC3403728. [Download]

854. Inceoglu, B., K.M. Wagner, J. Yang, A. Bettaieb, N.H. Schebb, S.H. Hwang, C. Morisseau, F.G. Haj and B.D. Hammock. 2012. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabete. Proc Natl Acad Sci U S A. 109(28):11390-5. PMCID: PMC3396532. [Download]

<<  < 1 2 3 4 5 6 7 8 9 > >> 

bottom of page